Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.

• Stifel analyst Stephen Willey initiated coverage on Lyell Immunopharma Inc (NASDAQ:LYEL) with a Buy rating and announced a price target of $36. Lyell Immunopharma closed at $13.45 on Wednesday. See how other analysts view this stock.
• HC Wainwright & Co. analyst Andres Y. Maldonado initiated coverage on Immuneering Corp (NASDAQ:IMRX) with a Buy rating and announced a price target of $14. Immuneering shares closed at $4.39 on Wednesday. See how other analysts view this stock.
• HC Wainwright & Co. analyst Mitchell S. Kapoor initiated coverage on Atrium Therapeutics Inc (NASDAQ:RNA) with a Buy rating and announced a price target of $25. Atrium Therapeutics closed at $11.74 on Wednesday. See how other analysts view this stock.

Considering buying LYEL stock? Here’s what analysts think:

Photo via Shutterstock

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.